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SYSTEMATIC REVIEW

von Willebrand factor levels in the diagnosis of von Willebrand disease:
a systematic review and meta-analysis
Mohamad A. Kalot,1 Nedaa Husainat,2 Abdallah El Alayli,3 Omar Abughanimeh,4 Osama Diab,5 Sammy Tayiem,6 Bader Madoukh,7
Ahmad B. Dimassi,8 Aref Qureini,9 Barbara Ameer,10 Jeroen C.J. Eikenboom,11 Nicolas Giraud,12 Claire McLintock,13 Simon McRae,14
Robert R. Montgomery,15,16 James S. O’Donnell,17 Nikole Scappe,18 Robert F. Sidonio, Jr 19 Romina Brignardello-Petersen,20
Veronica H. Flood,16 Nathan T. Connell,21 Paula D. James,22 and Reem A. Mustafa3

von Willebrand disease (VWD) is associated with signiﬁcant morbidity as a result of
excessive mucocutaneous bleeding. Early diagnosis and treatment are important to
prevent and treat these symptoms. We systematically reviewed the accuracy of
diagnostic tests using different cutoff values of von Willebrand factor antigen (VWF:Ag)
and platelet-dependent von Willebrand factor (VWF) activity assays in the diagnosis of
VWD. We searched Cochrane Central Register for Controlled Trials, MEDLINE, and
Embase databases for eligible studies. We pooled estimates of sensitivity and speciﬁcity
and reported patient-important outcomes when relevant. This review included 21 studies
that evaluated VWD diagnosis. The results showed low certainty in the evidence for a net
health beneﬁt from reconsidering the diagnosis of VWD vs removing the disease diagnosis in patients with VWF levels that have normalized with age. For the diagnosis of type 1
VWD, VWF sequence variants were detected in 75% to 82% of patients with VWF:Ag ,
0.30 IU/mL and in 44% to 60% of patients with VWF:Ag between 0.30 and 0.50 IU/mL. A
sensitivity of 0.90 (95% conﬁdence interval [CI], 0.83-0.94) and a speciﬁcity of 0.91 (95%
CI, 0.76-0.97) were observed for a platelet-dependent VWF activity/VWF:Ag ratio , 0.7 in
detecting type 2 VWD (moderate certainty in the test accuracy results). VWF:Ag and
platelet-dependent activity are continuous variables that are associated with an increase
in bleeding risk with decreasing levels. This systematic review shows that using a VWF
activity/VWF:Ag ratio , 0.7 vs lower cutoff levels in patients with an abnormal initial
VWD screen is more accurate for the diagnosis of type 2 VWD.

Submitted 7 June 2021; accepted 6 August 2021; prepublished online on Blood Advances First Edition 5 October 2021; ﬁnal version published online 30 December 2021.
DOI 10.1182/bloodadvances.2021005430.
The full-text version of this article contains a data supplement.
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Introduction
The reported prevalence of VWD is up to 1% in the general population based on epidemiologic studies1,2 with a symptomatic prevalence 0.1% at the level of primary care.3,4 The prevalence of
VWD is 15% in women with heavy menstrual bleeding, making it
the most common inherited bleeding disorder known in humans.5,6
VWD is caused by deﬁciency or dysfunction of VWF, a multimeric
glycoprotein that binds platelets at sites of vascular injury and stabilizes circulating coagulation factor VIII (FVIII).7-10

Multiple variables that affect VWF levels can make conﬁrming a
clear diagnosis of VWD difﬁcult. For example, estrogen therapy or
pregnancy will lead to an elevation in VWF, obscuring the diagnosis
of hereditary VWD in some women. Additionally, mildly reduced
VWF:Ag and platelet-dependent VWF activity levels do not always
establish a diagnosis of VWD; conversely, low normal VWF:Ag and
platelet-dependent VWF activity do not always exclude the diagnosis. This is related, in part, to the VWF:Ag assays, which have good
precision and reproducibility; however, the platelet-dependent VWF
activity assay has greater variability, resulting in the potential for misdiagnosis and/or misclassiﬁcation.13
Data show that 43% of previously diagnosed patients with partial
quantitative deﬁciency have normalized VWF levels with age.14-17
However, data are not available to show that an increase in VWF is
accompanied by improvement in symptoms. This results in the need
for health care providers to carefully consider excluding or removing
the diagnosis.
In addition to variation in the diagnosis and management, there is
limited awareness of the importance of VWD types and subtypes,
as well as lack of consensus on diagnostic criteria.18 The aim of this
systematic review was to determine the accuracy of different VWF
diagnostic thresholds (ie, VWF cutoff values) for the diagnosis of
VWD. Additionally, we assessed the potential beneﬁts and harms
from reconsidering the diagnosis of VWD vs simply removing the
diagnostic label of VWD from patients with VWF levels that have
normalized with age. The results were used to inform the recently
published evidence-based recommendations for clinical practice
guidelines on VWD, developed as a combined effort from the American Society of Hematology (ASH), the International Society on
11 JANUARY 2022 • VOLUME 6, NUMBER 1

Methods
Search strategy and data sources
We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from inception until August of 2019. We
also manually searched the reference lists of relevant articles and
existing reviews. Studies published in English were included in this
review. We limited the search to studies reporting data on the accuracy of diagnostic tests. The complete search strategy is available in
Supplement 1. The prespeciﬁed protocol for this review is registered with PROSPERO (CRD42020147977). This review is
reported in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses for diagnostic test accuracy
guidelines.21

Study selection
The eligibility criteria are discussed below.
Studies. We included studies reporting data on diagnostic test
accuracy (cohort studies, cross-sectional studies) for VWD.
Participants. Participants included patients, of any age, presenting to inpatient or outpatient settings with suspected VWD.
Index tests for diagnosis. The following tests were considered in eligible studies: VWF:Ag and platelet-dependent VWF activity (VWF ristocetin cofactor [VWF:RCo], VWF activity assays based
on ristocetin-induced binding of VWF to a recombinant wild-type
GPIb fragment, and VWF activity assays based on spontaneous
binding of VWF to a gain-of-function mutant GPIb fragment). We
did not exclude studies based on the timing of when the index test
was conducted.
Reference standards. If a reference diagnostic test was not
conducted, we accepted clinical follow-up for symptoms alone as a
reference standard.
Exclusion criteria. Although studies reporting on patients with
VWD, as well as other bleeding disorders, were eligible for inclusion, we excluded studies in which .80% of the study population
included a different bleeding disorder. When possible, we extracted
data separately for patients with VWD from these studies. We also
excluded studies that did not provide sufﬁcient data to determine
test accuracy (sensitivity and speciﬁcity), abstracts, and studies with
a sample size , 10 patients.

Screening and data extraction
Independent reviewers conducted title and abstract screening and
full-text review in duplicate to identify eligible studies. Two reviewers
completed data extraction independently and in duplicate, and data
were veriﬁed by a third reviewer (M.A.K.). Disagreements were
resolved by discussion to reach consensus, in consultation with 2
VWF LEVELS IN THE DIAGNOSIS OF VWD
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Patients with VWD can experience easy bruising, bleeding from
the oral cavity, heavy menstrual bleeding, as well as bleeding
after dental work, surgical procedures, and childbirth. Joint bleeding may also occur in more severe deﬁciency. These symptoms
vary among patients with VWD, and the bleeding phenotype can
ﬂuctuate throughout the life of a patient with VWD, leading to the
need for accurate diagnosis of VWD types and subtypes and
individualized management plans.11,12 Different types and subtypes of VWD have been deﬁned depending on the type of
abnormality in VWF. A patient with partial quantitative deﬁciency
in VWF would have type 1 VWD, whereas a patient with virtual
absence of VWF would have type 3 VWD. Patients with type 2
VWD have qualitative abnormalities of VWF: type 2A is characterized by reduced or absent high molecular weight VWF, type
2B results from a gain of function in VWF that increases its afﬁnity for platelets, type 2M is caused by reduced VWF interactions
with platelets or collagen, and type 2N results from reduced
binding of VWF to FVIII.2,5,10

Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation, the World Federation of Hemophilia, and the University of
Kansas Medical Center.19,20 The guidelines aim to inform all stakeholders on essential issues where there is variation or uncertainty in
clinical practice, and they will support decision making in the context
of patients’ values and preferences.

Table 1. GRADE test accuracy evidence summary for using different VWF levels to diagnose type 1 VWD
Certainty assessment
Studies, n

Study
design

Risk of
bias

Other
Inconsistency Indirectness Imprecision considerations

Impact

Certainty

Mutation detection
327,31,a

Observational Not serious*

Not serious

Not serious

Not serious

None

For VWF:Ag , 0.3, mutations were detected in 75-82%
of patients in 2 studies.
For VWF:Ag 5 0.3 to 0.5, mutations were detected
in 44-60% of patients in 3 studies.

⨁⨁
Low

Observational Not serious*

Not serious

Not serious

Not serious

None

In patients who were investigated for bleeding episodes, for
VWF:Ag levels 30-40 dL, LR of having VWD 5 1 (in all of
them, VWD was conﬁrmed by second-level tests). For levels
41-50 dL, LR 5 0.73 (0.41-1.30), and for levels 51-60 dL, LR
5 0.33 (0.18-0.62).13
Using MCMDM-1VWD, in patients with VWD and family history
of VWD, for VWF:Ag level , 20, LR 5 374 (52.2-2677); for
level 20-40, LR 5 95.1 (39.1-232); for level 40-60, LR 5 1.82
(1.28-2.58); and for level . 60, LR 5 0.10 (0.06-0.16).b

⨁⨁
Low

Serious†

Not serious

Not serious

None

The majority of patients with low VWF had signiﬁcant bleeding
histories, as determined using the ISTH BAT or the Condensed
MCMDM-1 VWD score.27
There was no difference between BS and VWF levels because
the BS used was after patients were recruited in the study and
were receiving treatment. Data from unpublished work showed
a continuum, with a higher BS in those with lower VWF at the
time of enrollment/diagnosis.a

⨁
Very low

Not serious

Not serious

Not serious

None

70 of 93 (75%) patients with borderline VWF (0.3-0.5) were
investigated after a bleeding episode: mucocutaneous bleeding
was present in 35, 25 bled after surgery, and 10 bled after
dental procedures. Ten patients experienced .1 symptom.

⨁⨁
Low

LR of VWD
213,b

227,a

Observational Not serious*

Bleeding tendency
113

Observational Not serious*

BAT, bleeding assessment tool; BS, bleeding score; LR, likelihood ratio; MCMDM-1 VWD, Molecular and Clinical Marker for the Diagnosis and Management of Type 1 (MCMDM-1)
VWD Bleeding Questionnaire.
*The majority of included studies were judged to be at a low risk for bias for patient selection and reference standard interpretation. Although there was unclear reporting about when
the index test was conducted, the certainty of evidence was not downgraded for risk of bias. The index test risk of bias was moderate in 7 cohort studies.
†Results from the 2 studies are not consistent with one another.
a
Flood,36 . . 2016.
b
Tosetto,37 . . 2007.

Table 2. Study characteristics for diagnosing type 2 VWD using VWF:RCo/antigen ratio
Study

Total patients (type 2M VWD), n

Cross-sectional, case control

142 (8)

PFA, RIPA, VWF:Ag, FVIII:C,
VWF:CB, molecular diagnosis
through DNA sequencing

37

de Maistre et al, 201433

Cross-sectional, case control

80 (16)

Molecular analysis was performed
to conﬁrm the classiﬁcation.

58

Chen et al, 201132

Cross-sectional, case control

453 (4)

Based on results of VWF:Ag,
VWF:RCo, and VWF multimer
analysis and available clinical
information, samples were
categorized as normal; VWD
types 1, 2A/B, 2M, or severe 1
vs 2M; or AVWA as a result of
the subtle loss of highest
molecular weight multimers.

6

James et al, 200731

Cross-sectional, case control

16 (all)

A blood sample was obtained
from all of the index cases, and
genomic DNA was isolated
from leukocytes using a saltextraction method.

N/A

Caron et al, 200630

Cross-sectional, case control

31 (0)

RIPA and genetic testing

N/A

Cross-sectional, cohort

497 (1)

VWF multimeric analysis,
VWF:Ag, ristocetin cofactor
activity, and collagen-binding
activity

10

Vangenechten et al, 2018

29

Adcock et al, 2006

Reference standard

Prevalence, %

Study design
34

AVWA, acquired VWF abnormalities; FVIII:C, FVIII activity; FVIII:CB, FVIII collagen binding; N/A, Not available; PFA, platelet function analyzer; RIPA, ristocetin-induced platelet
aggregation.
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VWF level and BS correlation

Identification

Records identified through
database searching
(n = 6,216)

Eligibility

Records excluded
(n = 5,024)

Records screened
(n = 5,693)

Full-text articles assessed
for eligibility
(n = 669)

Included

Studies included in qualitative synthesis
of VWD diagnosis systematic reviews
(n = 106)

Full-text articles excluded
(n = 563):
•
•
•
•
•
•

Duplicate (n = 4)
Incorrect study design/type (n = 150)
Incorrect population (n = 64)
No diagnostic tests of interest (n = 93)
Unacceptable reference standard (n = 47)
Not enough information to determine
test for VWD (n = 182)
• Sample size <10 pts (n = 23)

Studies included in quantitative
synthesis of Bleeding Assessment
tools Meta-Analysis
(n = 22)

Figure 1. Flow diagram for included studies. pts, patients.

expert clinician scientists (N.T.C. and P.D.J.). We extracted data
about general study characteristics (investigators, publication year,
country, study design), diagnostic index test and reference standard,
prevalence of VWD, and parameters to determine test accuracy (ie,
sensitivity and speciﬁcity of the index test).

Risk of bias and certainty of evidence
We conducted the risk of bias assessment for diagnostic test
accuracy studies using the Quality Assessment of Diagnostic
Accuracy Studies 2 revised tool.22 We used the Grading of Recommendations Assessment, Development and Evaluation
(GRADE) framework to assess overall certainty by evaluating the
evidence for each outcome on the following domains: risk of
bias, imprecision, inconsistency, indirectness, and publication
bias.23,24
11 JANUARY 2022 • VOLUME 6, NUMBER 1

Data synthesis
When feasible, we combined the accuracy estimates from individual
studies quantitatively (ie, pooled) for each test using Open MetaAnalyst. We conducted a bivariate analysis for pooling sensitivity
and speciﬁcity for each of the test comparisons to account for variation within and between studies. Forest plots were created for each
comparison. The Breslow-Day test was used to measure the percentage of total variation across studies due to heterogeneity (I2);
however, the results did not inﬂuence our judgment about inconsistency because of the known methodological limitations of I2 in test
accuracy reviews.25
Diagnostic strategies for VWD are based on assessment of the pretest probability (PTP) for individual patients, which provides an estimate of the expected prevalence of VWD at a population level. We
VWF LEVELS IN THE DIAGNOSIS OF VWD
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Screening

Records after duplicates removed
(n = 5,693)

Table 3. GRADE test accuracy evidence summary for using a platelet-dependent VWF activity assay/VWF:Ag ratio , 0.7 to diagnose
type 1 VWD
Factors that
may decrease CoE
Outcome
True positives*

Studies/
patients, n

Study
design

5/204

Cohort and
case-control
type studies

Serious†

Cohort and
case-control
type studies

Serious†

False negatives‡
True negatives§

4/994

False positives#

Risk of
bias

Indirectness

Inconsistency

Imprecision

Not serious

Not serious

Not serious

Effect per
1000 patients tested;
pretest probability of 30%

Publication bias
None

⨁⨁⨁
Moderate

278 (260-295)
22 (5-40)

Not serious

Serious¶

Seriousjj

None

Test accuracy
CoE

⨁
Very low

573 (441-700)
127 (0-259)

calculated the absolute differences in effects for each comparison
as true positives, true negatives, false positives, and false negatives.
Here, we present the results for the low-, intermediate-, and highPTP groups.

Results

answered the questions addressed in this systematic review.1417,26-34
A list of excluded studies is provided in Supplement 3.
Reasons for exclusion at full-text review were ineligible study
design, study population, or diagnostic test; sample size , 10
patients; unacceptable reference standards; and/or not enough
information to determine diagnostic test accuracy for VWD. Figure
1 summarizes the ﬂow diagram of the included studies.

Description of studies
The initial search retrieved 5693 nonduplicate studies, of which
669 were included for full-text review. Following full-text review, we
identiﬁed 106 studies eligible for data abstraction, of which 21

Studies
Vangenechten, K 2018
de Maistre, E 2014
Chen, D. 2011
Caron, C 2006
Adcock, D 2006

Sensitivity

Ev/Trt

0.920 (0.845, 0.995)
0.851 (0.749, 0.953)
0.857 (0.728, 0.987)
0.935 (0.849, 1.000)
0.990 (0.962, 1.000)

46/50
40/47
24/28
29/31
48/48

Use of different VWF levels to diagnose type 1 VWD
Of the included studies, 9 reported on the cutoff values of VWF.
Supplement 4 summarizes the general characteristics of the included

Overall (I2 = 6740%, P = 0.015) 0.925 (0.866, 0.984) 187/204
0.75

0.8

0.85

0.9

0.95

1

Sensitivity
Studies
Vangenechten, K 2018
de Maistre, E 2014
Chen, D. 2011
Adcock, D 2006

Specificity
0.724 (0.630, 0.818)
0.848 (0.726, 0.971)
0.991 (0.981, 1.000)
0.708 (0.666, 0.750)

Ev/Trt
63/87
28/33
421/425
318/449

0.001) 0.819 (0.630, 1.008) 830/994
Overall (I2 = 9848%, P 
0.65

0.7

0.75

0.8

0.85

Specificity
Figure 2. Forest plots for sensitivity and speciﬁcity for individual studies and the pooled estimates for a ratio < 0.7.
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Sensitivity, 0.93 (95% CI, 0.83-0.94); speciﬁcity, 0.82 (95% CI, 0.63-0.99). Pooled in proportion; not enough studies to pool as test accuracy results.
CoE, certainty of the evidence.
*Patients with type 2 VWD.
†All included studies were judged to be low risk of bias for test. Although there was unclear reporting about when the index test was conducted in some studies, the certainty of
evidence was generally not downgraded for risk of bias. The patient selection risk of bias was high because of the case control design and reference standard interpretation leading to
serious risk of bias.
‡Patients incorrectly classiﬁed as not having type 2 VWD.
§Patients without type 2 VWD.
¶Considering the upper vs the lower boundary of the effect estimate may lead to a different clinical decision.
jjPrevalences are 30%. This is typically seen in patients investigated for type 2 VWD because of a low VWF:RCo/antigen ratio.
#Patients incorrectly classiﬁed as having type 2 VWD.

Study

TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI)

Caron, 2006
James, 2007
Vangenechten, 2018

21
0 10 0
16
0
0 0
43 11
7 76

0.68 [0.49, 0.83]
1.00 [0.79, 1.00]
0.86 [0.73, 0.94]

Not estimable
Not estimable
0.87 [0.79, 0.94]
0

0.2 0.4 0.6 0.8

1 0

0.2 0.4 0.6 0.8

1

Figure 3. Forest plots for sensitivity and speciﬁcity for individual studies for a ratio < 0.6. FN, false negatives; FP, false positives; TN, true negatives; TP, true
positives.

Table 1 summarizes the evidence of using different VWF levels to
diagnose type 1 VWD. The interactive summary of ﬁndings can be
accessed using the following link: https://gdt.gradepro.org/presentations/#/isof/isof_c5b33e22-a646-4654-9f09-b820aff36c5c1569520689536?_k5eump67.

Use of platelet-dependent VWF activity/VWF:Ag
ratio to conﬁrm type 2 VWD
Of the included studies, 6 reported on the VWF level in type 2
VWD. Table 2 summarizes the general characteristics of included
studies, as well the index and reference standards. The complete
risk of bias assessment for individual studies is included in Supplement 4. The certainty of the evidence for test accuracy is very low,
which is due to the case-control design leading to serious
population-selection bias. The studies do not compare the 2 tests
cutoffs directly, and there is signiﬁcant unexplained inconsistency.
Test accuracy of a platelet-dependent VWF activity assay/
VWF:Ag ratio , 0.7 to conﬁrm type 2 VWD was pooled from 5
cohort studies that included 204 participants. Studies used laboratory testing, including a platelet function analyzer (PFA),

ristocetin-induced platelet aggregation (RIPA), VWF:Ag, FVIII
activity, VWF collagen binding, and molecular diagnosis through
DNA sequencing, as a reference standard for conﬁrming type 2
VWD. The pooled estimates for sensitivity and speciﬁcity were
0.93 (95% CI, 0.87-0.98) and 0.82 (95% CI, 0.63-0.99), respectively (moderate certainty in the sensitivity results and very low
certainty in the speciﬁcity results). Figure 2 shows the forest plot
displaying the sensitivity and speciﬁcity from individual studies
and the pooled estimates.
Table 3 shows GRADE test accuracy evidence summary when
using a platelet-dependent VWF activity assay/VWF:Ag ratio , 0.7
to diagnose type 1 VWD. The interactive summary of ﬁndings can
be accessed using the following link: https://gdt.gradepro.org/presentations/#/isof/isof_2e5b5dac-94e0-4108-9ff3-effcce27648b1606770452095?_k5r1ooaz.
We summarized the test accuracy using a platelet-dependent VWF
activity assay/VWF:Ag ratio , 0.6 to conﬁrm type 2 VWD from 3
cohort studies that included 184 participants. Studies used laboratory testing, including PFA, RIPA, VWF:Ag, FVIII:C, VWF:CB, and
molecular diagnosis through DNA sequencing, as a reference standard for conﬁrming type 2 VWD, with some studies also including a
clinical historic diagnosis. The ranges for estimates for sensitivity
and speciﬁcity were 0.68 to 0.97 and 0.87 to 0.88, respectively
(very low certainty in the sensitivity results and low certainty in the
speciﬁcity results). Figure 3 shows the forest plot displaying the
sensitivity and speciﬁcity from individual studies.

Table 4. GRADE test accuracy evidence summary for using a platelet-dependent VWF activity assay/VWF:Ag ratio , 0.6 to diagnose
type 1 VWD
Factors that
may decrease CoE
Outcome
True positives*

Studies/
patients

Study
design

3/97

Cohort
and case-control
type

Serious†

Cohort
and case-control
type

Serious†

False negatives¶
True negativesjj
False positives#

1/87

Risk
of bias

Indirectness

Inconsistency

Imprecision

Not serious

Serious‡

Serious§

Publication bias
None

Effect per
1000 patients tested;
pretest
probability of 30%
203-291
9-97

Not serious

Not serious

Serious

None

612
88

Test
accuracy CoE
⨁
Very low
⨁⨁
Low

Sensitivity, 0.68-0.97, speciﬁcity, 0.87-0.88.
Prevalences are 30%; typically seen in patients investigated for type 2 VWD because of a low VWF:RCo/Ag ratio.
CoE, certainty of the evidence.
*Patients with type 2 VWD.
†Serious patient selection risk of bias due to the case-control design. Also, issues around labeling as type 2M were noted.
‡Conﬁdence intervals do not cross the effect estimates of different studies.
§Small number of subjects.
¶Patients incorrectly classiﬁed as not having type 2 VWD.
jjPatients without type 2 VWD.
#Patients incorrectly classiﬁed as having type 2 VWD.
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studies, as well as the index and reference tests. The complete risk
of bias assessment for individual studies is included in Supplement
5. There was very low certainty in the evidence supporting the use
of different VWF levels to diagnose type 1 VWD and assessing the
implications and consequences of using different levels.

Study

TP FP FN TN Sensitivity (95% CI)

Adcock, 2006
Caron, 2006
James, 2007

38
18
10

0 10
0 13
0
6

0
0
0

0.79 [0.65, 0.90]
0.58 [0.39, 0.75]
0.63 [0.35, 0.85]

Specificity (95% CI)
Not estimable
Not estimable
Not estimable

Sensitivity (95% CI)

Specificity (95% CI)

0.2 0.4 0.6 0.8

0.2 0.4 0.6 0.8

0

1 0

1

Figure 4. Forest plots for sensitivity and speciﬁcity for individual studies for a ratio < 0.5. FN, false negatives; FP, false positives; TN, true negatives; TP, true
positives.

We summarized the test accuracy using a 0.5 plateletdependent VWF activity/VWF:Ag ratio , 0.5 to conﬁrm type 2
VWD from 3 cohort studies that included 95 participants. Studies used laboratory testing, including PFA, RIPA, VWF:Ag,
FVIII:C, VWF:CB and molecular diagnosis through DNA
sequencing, as a reference standard for conﬁrming type 2 VWD,
with some studies also including clinical historic diagnosis. The
range for estimates for sensitivity was 0.58 to 0.79; speciﬁcity
was assumed to be 1 with a ratio , 0.5 (low certainty in the sensitivity results). Figure 4 shows the forest plot displaying the sensitivity and speciﬁcity from individual studies.
Table 5 shows GRADE test accuracy evidence summary when
using a platelet-dependent VWF activity assay/VWF:Ag ratio , 0.5
to diagnose type 1 VWD.

Normalization of VWF levels with age
Of the included studies, 6 reported on VWF levels that normalize with
age in type 1 VWD. The risk of bias due to confounding factors was
high, because the studies did not adjust for comorbidities, with the
exception of the one by Sanders et al26; more elderly patients reported
$1 comorbidity, including diabetes, cancer, cardiovascular disease,
and depression, compared with younger patients. Atiq et al35 showed
that comorbidities are associated with higher levels of VWF and FVIII

in type 1 VWD, which may explain the age-related increase in VWF
and FVIII levels. The complete risk of bias assessment for individual
studies is included in Supplement 4. Table 6 summarizes the evidence
assessing normalization of VWF levels with age.

Discussion
VWF level cutoffs in the diagnosis of type 1 VWD
This review presents pooled and summary estimates of test accuracy and patient-important outcomes for different VWF levels for
VWD diagnosis and the reconsideration of the diagnosis in patients
with VWF levels that have normalized with age. Sequence variants
within VWF were identiﬁed more frequently in cases with lower
VWF levels. The beneﬁt of using a higher cutoff for type 1 VWD is
to not miss the diagnosis in an affected patient especially in those
with a bleeding phenotype. The beneﬁt of using a lower cutoff is to
avoid mistreating (or providing unnecessary treatment to) a patient
who does not have type 1 VWD. Consequently, it is reasonable to
use a VWF level of , 0.30 IU/mL regardless of bleeding phenotype, and in patients with abnormal bleeding, a VWF level of ,
0.50 IU/mL to conﬁrm the diagnosis of type 1 VWD. However, recommendations on whether to use a 0.30 IU/mL or 0.50 IU/mL level
in the clinical practice will depend on multiple factors, including the
patients’ values in regards to their diagnosis. Also, VWF antigen
and platelet-dependent activity are continuous variables with an
increase in bleeding risk with decreasing levels. However, the clinical phenotype is determined by more than the levels only.

Table 5. GRADE test accuracy evidence summary for using a platelet-dependent VWF activity assay/VWF:Ag ratio , 0.5 to diagnose
type 1 VWD
Factors that may
decrease CoE
Outcome
True positives*

Studies/
patients, n
3/95

False negatives§
True negatives¶
False positivesjj

Study
design

Risk
of bias Indirectness Inconsistency

Cohort and
Serious†
case-control type

Not serious

Not serious

Imprecision
Serious‡

Publication
bias
None

Effect per
1000 patients tested;
Test
pretest probability of 30% accuracy CoE
174-237
63-126

0/0

693-700
0-7

Sensitivity, 0.58-0.79; speciﬁcity 0.99-1.00. Speciﬁcity assumed to be 100% with a ratio cutoff , 0.5.
Prevalences are 30%; typically seen in patients investigated for VWD because of a personal history of abnormal laboratory test (eg, increased partial thromboplastin time).
CoE, certainty of the evidence.
*Patients with type 2 VWD.
†Serious patient selection risk of bias due to case-control design. Also, issues around labeling as type 2M were noted.
‡Small number of subjects.
§Patients incorrectly classiﬁed as not having type 2 VWD.
¶Patients without type 2 VWD.
jjPatients incorrectly classiﬁed as having type 2 VWD.
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Table 4 shows the GRADE test accuracy evidence summary when
using a platelet-dependent VWF activity assay/VWF:Ag ratio , 0.6
to diagnose type 1 VWD.

Table 6. GRADE evidence summary assessing the effect of normalization of VWF levels with age
Certainty assessment
Studies, n

Study
design

Risk
of bias

Other
Inconsistency Indirectness Imprecision considerations

Impact

Certainty

Age change in VWF:Ag
5

Observational Serious*

Serious‡

Not serious

None

5 studies with 1142 patients reported the change in VWF
levels longitudinally (follow-up between 1 and 10 y). The
mean change in VWF was 7.9 IU/dL per decade (range,
3.0-24.0).

⨁
Very low

Serious§

Serious‡

Not serious

None

4 studies with 435 patients reported the normalization of
VWF levels over a period of 1-10 y. The number of patients
with normalized levels ranged from 25-60%,
with a weighted average of 43%.

⨁
Very low

Not
serious

Not serious

Not serious

None

Binary logistic regression analysis with bleeding in the year
prior to inclusion in the WiN study as a dependent variable.
After adjusting for age, sex, BMI, and the presence of any
relevant comorbidities (hypertension, cancer, diabetes, and
thyroid dysfunction), normalization of VWF levels . 0.50
was still not associated with the incidence of bleeding
requiring treatment in the year prior to inclusion in the study
(odds ratio, 1.26; 95% CI, 0.72-2.21; P 5 .414). We can
conclude that, even after taking other important factors that
inﬂuence VWF levels and bleeding into account,
normalization of VWF levels is not associated with a lower
incidence of bleeding episodes requiring hemostatic
treatment. 27% of patients with normalized levels had
bleeding symptoms at the time of the study, and 21% of
patients with abnormal levels had bleeding symptoms.

⨁⨁
Low

Not
serious

Serious¶

Not serious

None

Nummi et al15 showed that the mean BS in patients with a
conﬁrmed diagnosis ranged between 10 and 24. Mean BS
in patients with a diagnosis of low VWF and those with
normal VWF levels was 6. Including all patients with
historical VWD, BS showed a weak and negative
correlation with VWF:RCo (r 5 10.43), VWF:Ag (r 5
10.51), VWF:CB (r 5 10.54), FVIII (r 5 10.44), RIPA, 0.6
mg/mL (r 5 10.34), and RIPA, 0.8 mg/ mL (r 5 10.54)
and a positive correlation with PFA C/EPI (r 5 10.45) and
C/ADP (r 5 10.46) (P # .001 for all). Sanders et al26
showed that BS did not differ between elderly and younger
patients.

⨁
Very low

Serious†

Frequency of normalization of VWF levels
4

Observational Serious*

1

Observational

Not
serious

BS in patients with normalized levels
2

Observational Serious*

BMI, body mass index; BS, bleeding score; C/ADP,Cartridge with collagen and adenosine diphosphate; C/EPI, Cartridge with collagen and epinephrine; PFA, Platelet Function
Analyser; RIPA, RIPA, ristocetin-induced platelet aggregation; VWF:CB, VWF collagen binding assay.
*Serious study confounding occurred because the investigators did not adjust for comorbidities, with the exception of Sanders et al26.. In their study, more elderly patients reported $1
comorbidity, including diabetes, cancer, cardiovascular disease, and depression, compared with younger patients. Atiq, 2018 showed that comorbidities are associated with higher levels
of VWF and FVIII in type 1 VWD and may explain the age-related increase in VWF and FVIII levels.
†The change in VWF levels varies between 3.0 and 24 IU/dL per decade, leading to serious inconsistency.
‡Although the change in VWF levels is presented, the bleeding symptoms of patients with normalized levels is not reported in the studies.
§The normalization of VWF levels varies between 25% and 60%, leading to serious inconsistency.
¶The BS does not predict the bleeding symptoms in patients in normal VWF levels but informs on the bleeding history in those patients.

VWF activity/VWF:Ag ratio in the diagnosis of
type 2 VWD
With regard to the platelet-dependent VWF activity/VWF:Ag ratio
for the diagnosis of type 2 VWD, the pooled estimates for sensitivity
and speciﬁcity for a ratio , 0.7 were higher than for the ratio , 0.5
and the ratio , 0.6. More false negatives are expected when using
a diagnostic threshold , 0.50 IU/mL. Therefore, it would be
appropriate to use a higher cutoff of , 0.7 to conﬁrm type 2
VWD (2A, 2B, or 2M) in patients with an abnormal initial VWD
screen. Quality of life and inaccurate counseling are concerns for
patients when they are mislabeled. Some pregnant women are
denied epidural anesthesia because they are labeled as having
type 2 VWD, but this is less of a problem for type 1 VWD. Of
note, when treatment is available it supports not denying epidural
11 JANUARY 2022 • VOLUME 6, NUMBER 1

anesthesia; however, the decision is more complex and should
be based on informed shared decision making with informed discussions about beneﬁts and harms. It is very important for clinicians and patients to understand the differences in treatment for
the different types of VWD.

Diagnosis in patients with VWD whose VWF levels
normalize with age
For patients with VWF levels that normalize with age, this should
trigger repeat evaluation of the bleeding phenotype and consideration of other bleeding disorders, particularly if other hemostatic
testing (ie, platelet function testing) was not performed previously.
The degree of normalization may inﬂuence the decision about how
to manage minor procedures (ie, expectantly or pretreat). It is
VWF LEVELS IN THE DIAGNOSIS OF VWD
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Bleeding with normalization of levels

important to note that some treatments for VWD (ie, tranexamic
acid) are also effective for other bleeding disorders. If the diagnosis
is removed, there is a fear of undertreatment, particularly if the
patient has had prior issues with major bleeding.
This review has several strengths. The comprehensive and systematic approach used to identify studies makes it unlikely that relevant
ones were missed. Also, we assessed the certainty of evidence
using the GRADE framework and identiﬁed sources of bias.

Conclusions
This comprehensive systematic review synthesizes and evaluates
the accuracy of VWF levels in the diagnosis of VWD. Estimates of
sensitivity and speciﬁcity from this review were used to inform
evidence-based recommendations for a clinical practice guideline.
For clinical decision making, the prevalence of PTP for VWD in a
population, together with the sensitivity and speciﬁcity estimates,
should inﬂuence how patients are managed.
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